ArticleProceedings of the National Academy of Sciences of the United States of America2007
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02021422 (A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients), which is not on this map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients
Who cites it
85 citing papers in PubMed, 173 citations in OpenAlex.
- Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.Journal of translational medicine · 2017Trial
- A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.PloS one · 2012Trial
- CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.Cancer immunology, immunotherapy : CII · 2011Trial
- Role of Regulatory T Cells in Intracerebral Hemorrhage.Molecular neurobiology · 2025Review
- Tumor antigen‑specific interleukin‑10‑producing T‑cell response in patients with head and neck squamous cell carcinoma.Oncology letters · 2024Article
- Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.Pharmaceutics · 2023Review
- What do cancer-specific T cells 'see'?Discovery immunology · 2023Review
- Identification of Age-Associated Transcriptomic Changes Linked to Immunotherapy Response in Primary Melanoma.Current issues in molecular biology · 2022Article
- γδ T, NKT, and MAIT Cells During Evolution: Redundancy or Specialized Functions?Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- Harnessing Antitumor CD4Cancers · 2022Review
- Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.Frontiers in immunology · 2022Review
- Tox2 is required for the maintenance of GC TScience advances · 2021Article
- Tumor resident regulatory T cells.Seminars in immunology · 2021Review
- Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment.Frontiers in immunology · 2021Review
- Effect of Heme Oxygenase-1 on Melanoma Development in Mice-Role of Tumor-Infiltrating Immune Cells.Antioxidants (Basel, Switzerland) · 2020Article
- Droplet encapsulation improves accuracy of immune cell cytokine capture assays.Lab on a chip · 2020Article
- Prognostic significance of serum carcinoembryonic antigen and squamous cell carcinoma antigen in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy.Translational cancer research · 2020Article
- Mechanisms of human FoxP3Clinical and experimental immunology · 2019Review
- T cell pathology in skin inflammation.Seminars in immunopathology · 2019Review
- The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design.Cancer immunology, immunotherapy : CII · 2019Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Although it is accepted that regulatory T cells (T regs) contribute to cancer progression, most studies in the field consider nonantigen-specific suppression. Here, we show the presence of tumor antigen-specific CD4(+) T regs in the blood of patients with metastatic melanoma. These CD4(+) T regs recognize a broad range of tumor antigens, including gp100 and TRP1 (melanoma tissue differentiation antigens), NY-ESO-1 (cancer/testis antigen) and survivin (inhibitor of apoptosis protein (IAP) family antigen). These tumor antigen-specific T regs proliferate in peripheral blood mononuclear cells (PBMC) cultures in response to specific 15-mer peptides, produce preferentially IL-10 and express high levels of FoxP3. They suppress autologous CD4(+)CD25(-) T cell responses in a cell contact-dependent manner and thus share properties of both naturally occurring regulatory T cells and type 1 regulatory T cells. Such tumor antigen-specific T regs were not detected in healthy individuals. These tumor antigen-specific T regs might thus represent another target for immunotherapy of metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.